The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD, despite the availability of two highly efficacious approved therapies—Genentech’s Lucentis and Regeneron’s Eylea. These current therapies, all of which target vascular endothelial growth factor (VEGF) and have been shown to maintain and even improve visual acuity in wet AMD patients, compete directly for patient share. It is essential to understand the use of these agents in the nuanced wet AMD treatment algorithm ahead of anticipated product launches. Our Treatment Algorithms Claims Data Analysis content provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Lucentis, Avastin, Eylea, Visudyne, Macugen
Key analysis provided:
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.